company background image
ALIVUS logo

Alivus Life Sciences NSEI:ALIVUS Stock Report

Last Price

₹1.20k

Market Cap

₹147.1b

7D

4.4%

1Y

37.8%

Updated

31 Jan, 2025

Data

Company Financials +

Alivus Life Sciences Limited

NSEI:ALIVUS Stock Report

Market Cap: ₹147.1b

ALIVUS Stock Overview

Engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. More details

ALIVUS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance2/6
Financial Health6/6
Dividends2/6

Rewards

Earnings are forecast to grow 27.44% per year

Risk Analysis

Dividend of 1.87% is not well covered by earnings or free cash flows


My Notes

Capture your thoughts, links and company narrative

Alivus Life Sciences Limited Competitors

Jubilant Pharmova

BSE:530019

₹154.0b

Granules India

BSE:532482

₹134.8b

Sanofi India

BSE:500674

₹127.3b

Aether Industries

NSEI:AETHER

₹109.9b

Price History & Performance

Summary of share price highs, lows and changes for Alivus Life Sciences
Historical stock prices
Current Share Price₹1,200.25
52 Week High₹1,335.10
52 Week Low₹676.50
Beta0.15
1 Month Change17.87%
3 Month Change14.20%
1 Year Change37.75%
3 Year Change111.16%
5 Year Changen/a
Change since IPO60.35%

Recent News & Updates

Recent updates

Glenmark Life Sciences Limited Recorded A 7.3% Miss On Revenue: Analysts Are Revisiting Their Models

Aug 07
Glenmark Life Sciences Limited Recorded A 7.3% Miss On Revenue: Analysts Are Revisiting Their Models

A Look At The Fair Value Of Glenmark Life Sciences Limited (NSE:GLS)

May 10
A Look At The Fair Value Of Glenmark Life Sciences Limited (NSE:GLS)

Why Investors Shouldn't Be Surprised By Glenmark Life Sciences Limited's (NSE:GLS) Low P/E

Feb 15
Why Investors Shouldn't Be Surprised By Glenmark Life Sciences Limited's (NSE:GLS) Low P/E

Shareholder Returns

ALIVUSIN PharmaceuticalsIN Market
7D4.4%-4.0%-1.8%
1Y37.8%20.3%6.2%

Return vs Industry: ALIVUS exceeded the Indian Pharmaceuticals industry which returned 20.3% over the past year.

Return vs Market: ALIVUS exceeded the Indian Market which returned 6.2% over the past year.

Price Volatility

Is ALIVUS's price volatile compared to industry and market?
ALIVUS volatility
ALIVUS Average Weekly Movement4.9%
Pharmaceuticals Industry Average Movement6.0%
Market Average Movement6.3%
10% most volatile stocks in IN Market9.1%
10% least volatile stocks in IN Market4.3%

Stable Share Price: ALIVUS has not had significant price volatility in the past 3 months compared to the Indian market.

Volatility Over Time: ALIVUS's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20112,014Yasir Rawjeewww.glenmarklifesciences.com

Alivus Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies.

Alivus Life Sciences Limited Fundamentals Summary

How do Alivus Life Sciences's earnings and revenue compare to its market cap?
ALIVUS fundamental statistics
Market cap₹147.07b
Earnings (TTM)₹4.42b
Revenue (TTM)₹22.74b

33.3x

P/E Ratio

6.5x

P/S Ratio

Is ALIVUS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALIVUS income statement (TTM)
Revenue₹22.74b
Cost of Revenue₹10.75b
Gross Profit₹11.99b
Other Expenses₹7.57b
Earnings₹4.42b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)36.05
Gross Margin52.73%
Net Profit Margin19.42%
Debt/Equity Ratio0.6%

How did ALIVUS perform over the long term?

See historical performance and comparison

Dividends

1.9%

Current Dividend Yield

0%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 17:53
End of Day Share Price 2025/01/31 00:00
Earnings2024/12/31
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Alivus Life Sciences Limited is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Saad ShaikhBOB Capital Markets Ltd.
Neha ManpuriaBofA Global Research
Nitin AgarwalDAM Capital Advisors